Prospects for the use of moxonidine (Physiotens®) in the prevention of bone resorption and aging of the vascular wall


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the analysis of the current literature regarding the new potentials for the use of moxonidine in hypertensive patients. Currently, moxonidine (Physiotens®) is the most frequently used sympatholytic, not only because of its pronounced effects on blood pressure, but due to additional metabolic effects. Several clinical studies have demonstrated high efficacy of moxonidine in prevention of development of insulin resistance and normalization of associated metabolic disorders. Organoprotective properties of moxonidine, in particular, cardio-, nephro-, and vasoprotective effects, are associated with a decrease in insulin resistance, decreased activity of the sympathetic-adrenal system. Particular attention is paid to the problem of vascular aging, telomere biology, insulin resistance, and calcium- phosphorus homeostasis. The possible ways to impact these processes, including the possible use of moxonidine, are consedered.

Full Text

Restricted Access

About the authors

Yekaterina Nailievna Dudinskaya

N.I. Pirogov Russian national research medical University; State scientific research center for preventive medicine

Email: katharina.gin@gmail.com
PhD, Head of Laboratory of age-related metabolic endocrine disorders of the Russian gerontological scientific clinical center; leading researcher of Department of the study of aging and prevention of age-associated diseases

Olga Nikolaevna Tkacheva

N.I. Pirogov Russian national research medical University; State scientific research center for preventive medicine

Email: tkacheva@rambler.ru
MD, professor, Head of the Russian gerontological scientific clinical center; Head of the Department of the study of aging and prevention of age-associated diseases

References

  1. Всемирный атлас профилактики сердечно-сосудистых заболеваний и борьбы с ними. Под ред. S. Mendis, P. Puska, B. Norrving. Всемирная организация здравоохранения. Женева, 2013. 155 с. [World atlas of cardiovascular diseases and struggle with them. Ed. by S. Mendis, P. Puska, B. Norrving. The world health organization. Geneva, 2013. 155 p. (in Russian)]
  2. Кардиоваскулярная профилактика. Национальные рекомендации. Разработаны Комитетом экспертов Всероссийского научного общества кардиологов. Москва, 2011. 64 с. [Cardiovascular prevention. The national recommendations. Developed by the Committee of experts of the Russian scientific society of cardiology. Moscow, 2011. 64 р. (in Russian)]
  3. Константинов В.В., Жуковский Г.С., Тимофеева Т.Н. и др. Распространенность артериальной гипертонии и ее связь со смертностью и факторами риска среди мужского населения в городах разных регионов. Кардиология. 2001;4:39 43. [Konstantinov V.V., Zhukovsky G.S., Timofeeva T.N. et al. Prevalence of hypertension and its relationship with mortality and risk factors among male population in cities of different regions. Kardiologiia. 2001;4:39-43 (in Russian)]
  4. Прохорович Е.А., Ткачева О.Н., Адаменко А.Н. Особенности клинического течения и лечения артериальной гипертонии у женщин. Трудный пациент. 2006;4(8):13-16. [Prokhorovich Ye.A., Tkacheva O.N., Adamenko A.N. Features of clinical flow and treatment of arterial hypertension at women. Difficult patient. 2006;4(8):13-16 (in Russian)]
  5. Virmani R., Avolio A.P., Mergner W.J., Robinowitz M., Herderick E.E., Cornhill J.F., Guo S.Y., Liu T.H., Ou D.Y., O'Rourke M. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am. J. Pathol. 1991;139:1 119-29.
  6. Fyhrquist F., Saijonmaa O., Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat. Rev. Cardiol. 2013;10:274-83.
  7. Ротарь О.П., Могучая Е.В., Костарева А.А., Конради А.О. Теломеры: реальная связь с сердечно-сосудистыми заболеваниями или чрезмерные надежды? РМЖ. 2012; 4:4-12 [Rotar O.P., Moguchaya Ye.V., Kostareva A.A., Konradi A.O. Telomeres: real association with cardio-vascular diseases or inflated expectations? Russian medical journal. 2012;34:4-12 (in Russian)]
  8. Бойцов С.А., Стражеско И.Д., Акашева Д.У., Дудинская Е.Н., Кругликова А.С., Ткачева О.Н. Инсулинорезистентность: благо или зло? Механизмы развития и связь с возраст-ассоциированными изменениями сосудов. Кардиоваскулярная терапия и профилактика. 2013; 12(4):91 -7. [Boytsov S.A., Strazhesko I.D., Akasheva D.U., Dudinskaya Ye.N., Kruglikova A.S., Tkacheva O.N. Insulin resistance: good or evil? Mechanisms of development and the relationship with age-associated vascular changes. Cardiovascular therapy and prevention. 2013;12(4):91-7 (in Russian)]
  9. Greider C.W., Blackburn E.H. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell. 1987;51:887-98.
  10. Blackburn E.H., Greider C.W., Henderson E., Lee M.S., Shampay J., Shippen-Lentz D. Recognition and elongation of telomeres by telomerase. Genome. 1989;31:553-60.
  11. Santos J.H., Meyer J.N., Skorvaga M., Annab L.A., Van Houten B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell. 2004;3:399-41 1.
  12. Ahmed S., Passos J.F., Birket M.J., Beckmann T., Brings S., Peters H., Birch-Machin M.A., von Zglinicki T., Saretzki G. Telomerase does not counteract telomere shorteningbut protects mitochondrial function under oxidative stress. J. Cell Sci. 2008;121:1046-53.
  13. Haendeler J., Dröse S., Büchner N., Jakob S., Altschmied J., Goy C., Spyridopoulos I., Zeiher A.M., Brandt U., Dimmeler S. Mitochondrial telomerase reverse transcriptasebinds to and protects mitochondrial DNA and function from damage. Arterioscler. Thromb. Vasc. Biol. 2009;29:929-35.
  14. Ornish D., Lin J., Daubenmier J., Weidner G., Epel E., Kemp C., Magbanua M.J., Marlin R., Yglecias L., Carroll P.R., Blackburn E.H. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008;9(1 1):1048-57.
  15. Gardner J.P., Li S., Srinivasan S.R., Chen W., Kimura M., Lu X., Berenson G.S., Aviv A. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111:2171-7.
  16. Vasan R.S., Demissie S., Kimura M., Cupples L.A., Rifai N., White C., Wang T.J., Gardner J.P., Cao X., Benjamin E.J., Levy D., Aviv A. Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Circulation. 2008;117:1138-44.
  17. Sengstock D.M., Vaitkevicius P.V., Supiano M.A. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J. Clin. Endocrinol. Metabol. 2005;90(5):2823-7.
  18. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002;1 10(2):229-38.
  19. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 1997;30(2):150-6.
  20. McCarron D.A., Pingree P.A., Rubin R.J., Gaucher S.M., Molitch M., Krutzik S. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinarycalcium leak. Hypertension. 1980;2(2):162-8.
  21. Zemel M.B., Zemel P.C., Bryg R.J., Sowers J.R. Dietary calcium induces regression of left ventricular hypertrophy in hypertensive non-insulin-dependent diabetic blacks. Am. J. Hypertens. 1990;3(6):458-63.
  22. Abedin M., Tintut Y., Demer L. Vascular calcification: mechanisms and clinical ramifications. Ateroscler. Thromb. Vasc. Biol. 2004;24:1 164-70.
  23. van Zwieten P.A. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J. Hypertens. 1997;15(Suppl. 1):S3-S8.
  24. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метабо- 119 лического синдрома. 2-й пересмотр. Кардиоваскулярная терапия и профилактика. 2009;6(Прил. 2): 1 -29. [The recommendations of the experts of the Russian scientific society of cardiology for the diagnosis and treatment of metabolic syndrome. 2nd revision. Cardiovascular therapy and prevention. 2009;6(Suppl. 2):1-29 (in Russian)]
  25. Алексанян Л.А., Полосьянц О.Б. Моксонидин в современном лечении кардиоваскулярных заболеваний. Российский медицинский журнал. 2006;4. [Alexanyan L.A., Pelosiyans O.B. Moxonidin in modern treatment of cardiovascular diseases. Russian medical journal. 2006;4 (in Russian)]
  26. Strojek K., Grzeszczak W., Gârska J., Leschinger M.I., Ritz E. Lowering of microalbuminuria in diabetic patients by sympaticoplegic agent: novel approach to prevent progression of diabetic nephropathy. J. Am. Soc. Nephrol. 2001;12:602-5.
  27. Krespi P. G., Makris T. K., Hatzizacharias A. N., Triposkiadis P., Stoical C., Kiribati D., Votteas V., Kyriakidis M. Moxonidine effect on microalbuminuria, trombomodulin and plasminogen activator ingibitor-1 levels in patients with essential hypertension. Cardiovasc. Drugs Ther. 1998;12:463-7.
  28. Waters J., Ashford J., Jager B.A., Wonnacott S., Verboom C.N. Use of moxonidine as unitial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (Trial of Physiotens in Combination) study. J. Clin. Basic Cardiol. 1999;2:219-24.
  29. Sharma A. M., Wagner Т., Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. Hum. Hypertens. 2004;18:669-75.
  30. Rapelli A. Hypertension and obesity in menopause. J. Hypertens. 2002;20:S26-S28.
  31. Подзолков В.И., Брагина А.Е., Гладышева Е.А. Роль моксонидина в комбинированной антигипертензивной терапии пациентов с метаболическим синдромом. Системные гипертензии. 2008;4:37-9. [Podzolkov V.I., Bragina A.Ye., Gladysheva Ye.A. Role of moxonidine in combined antihypertensive therapy of patients with metabolic syndrome. Systemic hypertensions. 2008;4:37-9 (in Russian)]
  32. Rupp H., Eisele B., Ziegler D. et al. United States patent. Method for the treatment of diseases requiring inhibition or reduction in the activity of pH value-regulating bicarbonate transporter proteins. US 7.309.706.B2. Dec 18, 2007
  33. Дудинская Е.Н., Ткачева О.Н. Дополнительные преимущества антигипертензивной терапии моксонидином у женщин с артериальной гипертонией в период постменопаузы. Кардиоваскулярная терапия и профилактика. 2014;13(1):8-15. [Dudinskaya Ye.N., Tkacheva O.N. Additional benefits of antihypertensive therapy moxonidine in women with arterial hypertension in postmenopause. Cardiovascular therapy and prevention. 2014;13(1):8-15 (in Russian)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies